SAG
SUPN icon

SageView Advisory Group’s Supernus Pharmaceuticals SUPN Stock Holding History

SageView Advisory Group’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-736
Closed -$36.6K – 2210
2025
Q4 		$36.6K Buy
+736
New +$35.8K ﹤0.01% 1203

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SageView Advisory Group's SUPN Position: Q1 2026 in Review

SageView Advisory Group sold out of Supernus Pharmaceuticals (SUPN) in Q1 2026, closing a stake of 736 shares — an estimated $36.6K sold.

SageView Advisory Group first reported a position in SUPN in Q4 2025 and held it in 1 quarter. The position peaked at $36.6K in Q4 2025. 328 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

  • SageView Advisory Group reported no remaining Supernus Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • SageView Advisory Group sold 736 Supernus Pharmaceuticals shares in Q1 2026, an estimated $36.6K.
  • SageView Advisory Group first reported a position in Supernus Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • SageView Advisory Group's Supernus Pharmaceuticals position peaked at $36.6K in Q4 2025.
  • 328 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on SageView Advisory Group's 13F filing for Q1 2026, filed 10 Aug 2026.